^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | icovamenib (BMF-219) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors Add to My Itinerary
Published date:
03/09/2022
Excerpt:
Human CRC, NSCLC and pancreatic ex vivo preclinical models with G12C, G12D, and G12V KRAS mutations were all sensitive to BMF-219 after a 6-day treatment….Complete abrogation of growth was observed in all samples with IC50 values ranging between 0.2 μM - 0.6 μM....High potency of BMF-219 was observed amongst various KRAS-mutant cell lines suggesting that BMF-219 broadly inhibits these tumors.
